Investigation of the effects of the blood plasma levels of C16 ceramides on the course of non-alcoholic fatty liver disease
Journal Title: Сучасна гастроентерологія - Year 2019, Vol 0, Issue 5
Abstract
Objective — to investigate the dependence of the blood plasma levels of C16 ceramides on the degree of liver steatosis in patients with nonalcoholic fatty liver disease (NAFLD) based on the results of steatomometry in comparison with healthy subjects. Materials and methods. The study involved 20 patients with NAFLD and 20 healthy people. Among them, 10 (50 %) were men and 10 (50 %) women. The mean age of patients was 50.2 ± 1.93 years. The mean body weight in the main group was 103.5 ± 1.9 kg, and the mean BMI was 33.1 ± 0.5. The men blood glucose level was 5.6 ± 0.1 mmol/L; HOMA index 2.4 ± 0.2. The results of steatometry showed the mean damping factor of 2.70 ± 0.2, which corresponded to S2 degree of liver steatosis. NAFLD diagnosis was verified based on patient’s complaints, anamnesis of the disease, objective examination including anthropometric parameters, laboratory methods (blood glucose, glycosylated hemoglobin, HOMA index), parameters of steatometry, elastometry and mass spectrometry liquid chromatography (Shimadzu Nexera X2 UHPLC, Shimadzu LCMS-8045 mass spectrometer). The control group consisted of 20 healthy age- and gender-matching subjects with normal body mass. Results. NAFLD patients demonstrated the significantly increased blood plasma levels of C16 ceramides up to 0.402 ± 0.01 μmol/L, compared to healthy subjects levels of 0.271 ± 0.01 μmol/L (p < 0.001), that corresponded to a moderate steatosis degree. The glucose levels and NOMA index in NAFLD patients were within the normal limits of 5.6 ± 0.1 mmol/L and 2.4 ± 0.2, respectively. Conclusions. The elevated blood plasma levels of C16 ceramides significantly (p < 0.001) affected the degree of steatosis compared to the healthy people, they proved to be more sensitive marker of insulin resistance.
Authors and Affiliations
L. L. Pavlovskyi, V. V. Chernyavskyi, V. P. Shipulin, L. M. Kupchyk
Keywords
Related Articles
- EP ID EP675095
- DOI 10.30978/MG-2019-5-14
- Views 118
- Downloads 0
The results of multicenter study of efficacy of Helicobacter pylori eradication therapy, conducted according to the recommendations of Maastricht V Consensus Report
Objective — to study efficacy and safety of two weeks quadruple therapy with high doses of pantoprazole, bismuth subcitrate, clarithromycin, amoxicillin with concomitant adjuvant symbiotic therapy (Saccharomyces boulardi...
The ways of antihelicobacter therapy in Ukraine (based on the data of analysis of the Ukrainian Registry Hp-EuReg — UKRAINE)
Objective — to assess the state of affairs in the diagnosis and treatment of Helicobacter pylori infection in Ukraine and their conformity with the modern international recommendations. Materials and methods. The perfor...
New possibilities for treatment of gastroesophageal reflux disease
Objective — to evaluate the clinical efficacy of the addition of Gyalera emulsion (Alpiflor SRL, Italy) to the standard therapy of patients with gastroesophageal reflux disease (GERD) and to study the effects of such tre...
The place of domperidone in the treatment of comorbid pathology of esophagus and stomach (a clinical case)
It has been established that around 20 % of patients with gastroesophageal reflux disease (GERD) have clinical symptoms of the functional gastric dyspepsia, and 20 — 30 % of patients with predominantly non-erosive reflux...
The overlap syndrome: combination of the autoimmune hepatitis with the primary biliary cholangitis
The overlap syndrome in hepatology traditionally defined as the simultaneous presence in a patient of clinical or laboratory signs of two different autoimmune liver diseases. The most common combination is autoimmune hep...